SCORPION THERAPEUTICS are targeting a different targets and mutations....
When I first bought into CHM I did a bunch of research and discovered there are LOADS of active / past studies utilizing CAR-T tech and lots of listed companies funding it - and far more universities and labs dedicated to pre-clinical studies of CAR-T. Initially this had me worried, but I quickly realized that this is just like any other technology - there is more than one way to make a brick or use a piece of wood.
Quite simply, Chlorotoxin has loads of potential applications and possible targets. The Chlorotoxin protein evolved in scorpions and their evolutionary relatives through HUNDREDS of millions of years of trial and error. So in a sense, nature has done 99.9999% of the work for us, in evolving these complex bio-active proteins:
"Hundreds of millions of years ago, when the ancestors of land animals crawled out of the seas and flopped on a primordial beach they learned quickly that to survive they were going to have to develop new tools for catching prey. Venom became one of these tools.
Scientists have found that in most cases all that is required to turn a protein vital for life into a substance that can kill is a mutation in one gene.
A group of scientists have discovered that is true of scorpions. A team led by Shunyi Zhu of the Institute of Zoology at the Chinese Academy of Sciences found that a common protein used as part of the scorpion's immune system was the origin of the scorpion's venom.The work is published online by Molecular Biology and Evolution.It is quite likely that a similar process was involved in the evolution of most of the venom in the animal world, Zhu said." See:
Most toxin based research comes from snake venom. If you were to look at any of the big peptide / enzyme dervived medicines, you would find a ton of research, offshoots and related biomedical applications:
"The first animal toxin-based drug approved for human use was captopril in 1981. Captopril (Capoten®, Bristol-Myers Squibb) was developed based on the bradykinin potentiating factor (BPF) present in Bothrops jararaca snake venom (Ferreira, 1965; Camargo et al., 2012)." See:
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)